Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
Limited treatment options are available for patients with relapsed/refractory acute myeloid leukemia (R/R AML). We recently reported results from the phase 3 IDHENTIFY trial (NCT02577406) showing improved response rates and event-free survival with enasidenib monotherapy compared with conventional c...
Main Authors: | , , , , , , , , , , , |
---|---|
פורמט: | Journal article |
שפה: | English |
יצא לאור: |
Elsevier
2024
|